The FDA will review Moderna’s mRNA flu shot, mRNA-1010, after initially refusing the application due to some made-up concern about the clinical trial design.
-
The FDA will review Moderna’s mRNA flu shot, mRNA-1010, after initially refusing the application due to some made-up concern about the clinical trial design. Moderna proposed a revised plan to seek full approval for adults 50-64 and accelerated approval for adults 65 and older, contingent on further testing. If approved, the vaccine could be available for the 2026-27 flu season.
-
The FDA will review Moderna’s mRNA flu shot, mRNA-1010, after initially refusing the application due to some made-up concern about the clinical trial design. Moderna proposed a revised plan to seek full approval for adults 50-64 and accelerated approval for adults 65 and older, contingent on further testing. If approved, the vaccine could be available for the 2026-27 flu season.
@davidho There's TACO Tuesdays for tariffs. There should be another term for drug approvals. Maybe Rebound Wednesdays?
-
The FDA will review Moderna’s mRNA flu shot, mRNA-1010, after initially refusing the application due to some made-up concern about the clinical trial design. Moderna proposed a revised plan to seek full approval for adults 50-64 and accelerated approval for adults 65 and older, contingent on further testing. If approved, the vaccine could be available for the 2026-27 flu season.
@davidho so, was the real objection "where's my bribe"?
-
R ActivityRelay shared this topic
